Literature DB >> 23824394

Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database.

Benjamin J Miller1, Peter Cram, Charles F Lynch, Joseph A Buckwalter.   

Abstract

BACKGROUND: Osteosarcoma is the most common primary bone sarcoma and affects all ages. There are substantial differences in management and outcomes for patients who have localized disease compared with distant spread at the time of diagnosis. Our goal was to examine potential risk factors predictive of metastatic disease at presentation.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify all patients diagnosed with osteosarcoma from 2000 to 2008 and to classify each patient as having metastatic or localized disease at the time of diagnosis. Patient-based characteristics, tumor characteristics, and county-level socioeconomic measures were analyzed to determine which factors were predictive of an increased rate of distant metastatic disease at presentation. These factors were analyzed as univariate characteristics as well as in a multivariate logistic regression model.
RESULTS: We identified 2017 cases of high-grade osteosarcoma, and 464 (23.0%) of the patients presented with metastatic disease. In the unadjusted logistic regression analysis, patients had increased odds of metastatic disease at presentation if they had an age of sixty years or more (odds ratio [OR] = 2.22; 95% confidence interval [CI], 1.71 to 2.89), had a tumor located in the axial skeleton (OR = 2.47; 95% CI, 1.88 to 3.26), and lived in a county with low socioeconomic status (OR = 1.59; 95% CI, 1.08 to 2.35). These factors remained significant when combined in multivariate models controlling for age, location, and socioeconomic status. For patients with recorded tumor size information (n = 1398), the odds of metastasis at presentation increased by 10% with each additional centimeter of tumor size (OR = 1.10; 95% CI, 1.08 to 1.13). When the patients with missing tumor size information were excluded, socioeconomic status was no longer a significant risk factor for metastasis at presentation in the multivariate model.
CONCLUSIONS: Osteosarcoma patients with advanced age, a tumor in the axial skeleton, a larger tumor size, and a residence in a less affluent county were more likely to have metastatic disease at presentation.

Entities:  

Mesh:

Year:  2013        PMID: 23824394      PMCID: PMC3689260          DOI: 10.2106/JBJS.L.01189

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  26 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis.

Authors:  Maxine Sun; Firas Abdollah; Daniel Liberman; Al'a Abdo; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Cancer       Date:  2011-03-08       Impact factor: 6.860

3.  The effect of local extent of the tumor on prognosis in osteosarcoma.

Authors:  S S Spanier; J J Shuster; R A Vander Griend
Journal:  J Bone Joint Surg Am       Date:  1990-06       Impact factor: 5.284

4.  Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients.

Authors:  M Fahey; S S Spanier; R A Vander Griend
Journal:  J Bone Joint Surg Am       Date:  1992-03       Impact factor: 5.284

5.  Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients.

Authors:  Matthew T Harting; Kevin P Lally; Richard J Andrassy; Ara A Vaporciyan; Charles S Cox; Andrea Hayes-Jordan; Martin L Blakely
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

6.  Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.

Authors:  G Bacci; A Briccoli; M Rocca; S Ferrari; D Donati; A Longhi; F Bertoni; P Bacchini; S Giacomini; C Forni; M Manfrini; S Galletti
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

7.  Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects.

Authors:  Stephanie A Robert; Indiana Strombom; Amy Trentham-Dietz; John M Hampton; Jane A McElroy; Polly A Newcomb; Patrick L Remington
Journal:  Epidemiology       Date:  2004-07       Impact factor: 4.822

8.  Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.

Authors:  Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

9.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

10.  Social and geographical factors affecting access to treatment of colorectal cancer: a cancer registry study.

Authors:  S Michael Crawford; Violet Sauerzapf; Robin Haynes; David Forman; Andrew P Jones
Journal:  BMJ Open       Date:  2012-04-24       Impact factor: 2.692

View more
  56 in total

1.  Strong expression of paired-like homeodomain transcription factor 1 (PITX1) is associated with a favorable outcome in human osteosarcoma.

Authors:  Gengbin Kong; Zhaoyong Liu; Kezhou Wu; Ying Zhang; Zhihua Deng; Weili Feng; Shubiao Chen; Hu Wang
Journal:  Tumour Biol       Date:  2015-05-04

Review 2.  Progress in the chemotherapeutic treatment of osteosarcoma.

Authors:  Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

3.  The value of chest and skeletal staging studies in conventional chondrosarcoma.

Authors:  Ines Oliveira; Nehal Singla; Anesh Chavda; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2020-07-14       Impact factor: 2.199

4.  CORR Insights®: Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.

Authors:  Benjamin J Miller
Journal:  Clin Orthop Relat Res       Date:  2016-04-05       Impact factor: 4.176

5.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

Review 6.  P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.

Authors:  Jie Bu; Hui Li; Li-Hong Liu; Yu-Rong Ouyang; Hong-Bin Guo; Xiao-Yang Li; Tao Xiao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

7.  Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

Authors:  Kehan Song; Xiao Shi; Xin Liang; Hongli Wang; Fei Zou; Feizhou Lu; Xiaosheng Ma; Jianyuan Jiang
Journal:  Int Orthop       Date:  2018-04-21       Impact factor: 3.075

8.  Osteogenic sarcoma of the skull: long-term outcome of a rare tumor.

Authors:  Ronette Goodluck Tyndall; Oana-Eugenia Popescu; Prevost Derek; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2018-08-17       Impact factor: 1.475

9.  A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.

Authors:  Lisa Mirabello; Roelof Koster; Branden S Moriarity; Logan G Spector; Paul S Meltzer; Joy Gary; Mitchell J Machiela; Nathan Pankratz; Orestis A Panagiotou; David Largaespada; Zhaoming Wang; Julie M Gastier-Foster; Richard Gorlick; Chand Khanna; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Ana Patiño-Garcia; Luis Sierrasesúmaga; Fernando Lecanda; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; Adrienne M Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Dina Halai; Mandy L Ballinger; David M Thomas; Sean Davis; Donald A Barkauskas; Neyssa Marina; Lee Helman; George M Otto; Kelsie L Becklin; Natalie K Wolf; Madison T Weg; Margaret Tucker; Sholom Wacholder; Joseph F Fraumeni; Neil E Caporaso; Joseph F Boland; Belynda D Hicks; Aurelie Vogt; Laurie Burdett; Meredith Yeager; Robert N Hoover; Stephen J Chanock; Sharon A Savage
Journal:  Cancer Discov       Date:  2015-06-17       Impact factor: 39.397

10.  Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma.

Authors:  Bo Li; Peng Ren; Zhiyong Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.